MOTS-c dosage calculator: why one doesn't really exist yet

Last updated 2026-07-25

Is there an actual MOTS-c dosage calculator backed by research?

No. Search around and you'll find plenty of web widgets that ask for your body weight and spit out a milligram number, but none of them are built from a published human pharmacokinetic study. That's the honest starting point for this whole topic. The foundational MOTS-c paper, the 2015 Cell Metabolism study that first characterized the peptide's metabolic effects, dosed mice at levels used to demonstrate reduced diet-induced obesity and improved insulin resistance ^[1]. That's a mouse study. It tells you MOTS-c does something biologically real in that model. It does not tell you what happens in a 175-pound human, because nobody has run that trial and published it. A 2023 review in Frontiers in Endocrinology calls MOTS-c "a promising mitochondrial-derived peptide for therapeutic exploitation," which is reviewer language for: interesting mechanism, early days, keep watching ^[2]. A 2026 Sports Medicine paper on peptide therapies used in musculoskeletal and athletic contexts specifically catalogs the safety and efficacy data (or lack of it) for approved versus unapproved peptides, and MOTS-c falls on the unapproved, data-poor side of that ledger ^[3]. Any calculator you see is interpolating from animal dosing and internet consensus, not a dose-ranging trial with pharmacokinetic sampling in humans. If you want the fuller picture on how people actually administer it in practice, our MOTS-c dosage page walks through the ranges people use and where those numbers originate.

How do people estimate a MOTS-c dose without human trial data?

Most estimates work backward from the animal literature using a body-weight scaling method, then apply a large safety discount. That's the honest mechanics behind almost every calculator you'll encounter. The process usually looks like this: take the mg/kg dose that produced an effect in mice in a study like the 2015 Cell Metabolism paper ^[1] or the 2018 Cell Metabolism paper describing MOTS-c's nuclear translocation under metabolic stress ^[4], apply an allometric scaling conversion (mice have faster metabolisms and clear compounds quicker than humans, so a straight per-kilogram translation overstates the human-equivalent dose), and then apply an arbitrary conservatism factor because nobody has confirmed that math with real pharmacokinetic sampling in people. The result is a number that feels precise but rests on several unverified assumptions stacked on top of each other. Community dosing in the peptide-use space (self-administered, unsupervised, and outside any clinical protocol) has converged on ranges in the low single-digit milligrams per week, split across two or three doses. That convergence is a social phenomenon, not a validated finding. It means a lot of people landed on similar numbers by copying each other, not that anyone ran a trial confirming those numbers are optimal or even safe long-term. A calculator that takes your weight and multiplies it by a fixed factor is doing exactly this extrapolation, just faster. It is not wrong to use as a rough planning tool. It is wrong to treat as clinically validated.

What inputs would a real MOTS-c dosage calculator need?

A legitimate dose calculator needs a confirmed human pharmacokinetic profile, a defined therapeutic window, and a stated route of administration, none of which currently exist in published form for MOTS-c. Here's what's missing, specifically. First, absorption and half-life data in humans: how fast does subcutaneously injected MOTS-c enter circulation, and how long does it stay active? The mechanistic work explaining what MOTS-c does once it's in a cell, including its translocation to the nucleus to regulate gene expression under metabolic stress ^[4] and its later-described role binding and activating CK2 in skeletal muscle ^[5], is cell-based and animal-based. None of it reports human injection-to-peak-concentration timing. Second, a therapeutic window: the blood concentration range where you get benefit without toxicity. Third, route-specific data, since intraperitoneal injection in a mouse study and a subcutaneous injection in a person are not interchangeable in absorption kinetics. Fourth, population variables, since body composition, kidney and liver function, age, and baseline metabolic status all plausibly shift dosing needs, and none of that has been mapped for this compound in humans. Until those four pieces exist in peer-reviewed form, any "calculator" is really a weight-based multiplier dressed up with a clean interface.

What does the animal research actually show about MOTS-c and dose?

The animal and cell data show a molecule with a genuinely wide range of biological activity: metabolic, muscular, cardiovascular, and beyond, but the specific doses used vary by study design and don't converge into one clean human translation. On metabolism, the 2015 Cell Metabolism paper found that MOTS-c administration reduced obesity and improved insulin resistance in diet-induced obese mice ^[1]. A 2023 paper in Metabolites, titled "MOTS-c Functionally Prevents Metabolic Disorders," adds to that mechanistic case ^[6]. In gestational diabetes specifically, a 2022 Pharmacological Research study found MOTS-c relieved hyperglycemia and insulin resistance in a GDM model ^[7]. A 2025 paper in Experimental & Molecular Medicine reported that MOTS-c prevents pancreatic islet cell senescence, potentially delaying diabetes onset in the models tested ^[8]. On muscle, a 2022 Peptides study found MOTS-c promotes muscle differentiation in vitro ^[9], a 2021 American Journal of Physiology paper found it reduces myostatin and muscle atrophy signaling ^[10], and a 2024 AJP-Endocrinology and Metabolism study found it attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration ^[11]. A 2024 iScience paper went further mechanistically, showing MOTS-c directly binds and activates CK2 to modulate skeletal muscle function ^[5]. On cardiovascular and pulmonary systems, a 2025 review in Cardiovascular Drugs and Therapy asks bluntly whether MOTS-c is a "magical molecule" for diabetic cardiomyopathy ^[12], while separate 2025 papers describe protective roles in lung ischemia-reperfusion injury via nuclear translocation ^[13] and in cardiopulmonary bypass-induced lung injury via an AMPK-HIF-1α-PFKFB3 glycolysis pathway ^[14]. Every one of these is a mouse, rat, or cell-culture finding. That's not a knock on the research; it's genuinely broad and mechanistically interesting work. It's a reminder that "the dose that worked in a diabetic mouse" and "the dose a healthy 40-year-old human should take" are not the same number, and nobody has published the bridge between them.

Does the 'exercise in a pill' claim affect how MOTS-c should be dosed?

No credible dosing protocol should be built around the "exercise in a pill" framing, because that phrase describes a research hypothesis about mitohormesis, not a demonstrated equivalence between injecting MOTS-c and doing a workout. The actual research question here is about mitohormesis: whether mild mitochondrial stress signals, of the kind exercise produces, can be mimicked by a mitochondrial-derived peptide. A 2022 review in Diabetes & Metabolism Journal, titled "Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c)," lays out that hypothesis directly ^[15]. A 2021 review in Biochimica et Biophysica Acta looked at mitochondrial-derived peptides and exercise more broadly ^[16]. Both are genuinely worth reading if you want the mechanistic argument. Neither is a human trial showing that a specific injected dose of MOTS-c produces the cardiovascular, metabolic, and muscular adaptations of, say, 150 minutes of weekly aerobic exercise. A 2025 Scientific Reports study found that MOTS-c mimicked exercise effects specifically in combating diabetic liver fibrosis in an animal model, working through the Keap1-Nrf2-Smad2/3 pathway ^[17]. That's a real, specific, citable finding. It is also one disease model, one pathway, one paper. Marketing copy that generalizes from findings like this to "MOTS-c replaces your workout" is doing exactly the kind of overreach this article is trying to flag. Use the mimetic framing to understand why researchers are interested in MOTS-c's mechanism. Don't use it to justify a dosing decision, and don't let it substitute for actual physical activity. Worth noting too: a 2018 paper in Rejuvenation Research, "Mitochondrial-Derived Peptides Exacerbate Senescence," is a reminder that this peptide family's effects are not uniformly protective across every context studied ^[18]. Complexity, not a clean story, is what the data actually shows.

What dose ranges show up in the non-metabolic MOTS-c research?

Doses vary widely across the non-metabolic literature too, which is more evidence that no single number generalizes across MOTS-c's biology. Below is a rough map of what's been studied, purely to illustrate the range, not to suggest translation to human self-dosing.

The throughline across this table is mechanistic: Nrf2 pathway activity, mitochondrial-nuclear signaling, and stress-response modulation keep showing up in different tissue contexts ^[28]. It is genuinely interesting that one small peptide touches this many systems. It is also exactly why one dosage number cannot serve all these purposes, since a dose optimized for, say, cartilage protection has no established relationship to a dose relevant to metabolic effects. Nobody has run comparative dose-ranging work across these indications, in humans or animals, that would let a calculator meaningfully differentiate them.

Is MOTS-c legal to obtain, and does that affect dosing guidance?

MOTS-c is not an FDA-approved drug for any indication, and its regulatory status directly limits what any dosing guidance, calculator or otherwise, can responsibly claim. Check Drugs@FDA and you won't find it listed as an approved product [FDA database]. That regulatory gap matters for two practical reasons. First, no FDA-reviewed label means no FDA-reviewed dosing instructions exist anywhere, for anyone. Second, MOTS-c's compounding status is genuinely unsettled: substances used in 503A compounding (individually prepared prescriptions) are governed by the bulk drug substance list under 21 CFR 216.23 [ecfr 216.23], and 503B outsourcing facilities operate under a separate bulks list at 21 CFR 216.24 [ecfr 216.24], with the underlying compounding authority set out in 21 U.S.C. 353a [21 USC 353a]. FDA maintains and updates its own list of nominated bulk substances under section 503A [FDA bulks page], and separately explains the framework for what qualifies at all [FDA 503A page]. Whether MOTS-c sits on either accepted list, and under what conditions, is a live regulatory question, not a settled one, and it can change. Practically: if a compounding pharmacy is legally providing MOTS-c under physician oversight, that provider relationship is also where any dosing decision should actually happen, informed by your specific health picture, not by a generic online calculator. That's the difference between a rough estimating tool and a medical decision made with someone who can see your labs.

How should you actually think about a MOTS-c dose if you're going to use one anyway?

If you're going to use MOTS-c despite the thin human evidence base, the responsible approach treats any dose number as a starting hypothesis to discuss with a provider, not a fixed prescription from a website. Start from a low end of whatever range a provider or compounding pharmacy suggests, track objective markers you can actually measure (fasting glucose, HbA1c, body composition, subjective energy and recovery), and give it enough time to notice a pattern before increasing anything. A four-week trial with baseline labs beats guessing your way to a bigger number because a forum thread said so. Be skeptical of any calculator, app, or online tool that gives you a precise milligram figure to two decimal places based only on your body weight. That level of false precision is a tell that the tool is extrapolating from mouse data through an unverified formula, not reflecting confirmed human pharmacokinetics. The 2026 Sports Medicine review on peptide therapies for musculoskeletal and athletic use makes a similar point in a broader context: many of these compounds are used well ahead of the safety and efficacy data needed to dose them with real confidence ^[3]. For the practical mechanics of how MOTS-c is typically administered, when in the day it's usually taken, where it's injected, and how long a typical cycle runs, those questions have their own dedicated answers: see how to take MOTS-c peptide, best time of day to take MOTS-c peptide, MOTS-c injection sites, and MOTS-c cycle length. None of those pages will give you a validated clinical dose either, because that data doesn't exist yet. What they can do is lay out current practice honestly, alongside its limits. If you do decide to move forward, the safer path is a provider-reviewed one: a clinician or compounding pharmacy that can evaluate your specific labs and health history, rather than a self-service calculator with no medical oversight behind it. MOTS-c Co's provider-reviewed sourcing guidance points toward that route rather than DIY dosing from an anonymous web tool.

What would it actually take to build a validated MOTS-c dosage calculator?

A validated calculator needs a published Phase 1 human dose-escalation trial with pharmacokinetic sampling, something that does not yet exist in the peer-reviewed literature for MOTS-c. Here is the honest checklist. A Phase 1 safety and pharmacokinetics study in healthy volunteers, establishing how the peptide is absorbed, distributed, and cleared at several dose levels. A Phase 2 dose-ranging study in a target population (people with insulin resistance, for instance, given how much of the preclinical interest centers on metabolic effects ^[1][7]) to identify a dose associated with measurable benefit versus one that isn't. Published data on interindividual variability, since body weight alone is unlikely to be the only relevant variable. And ideally, replication: more than one trial confirming the same dose-response relationship, because single studies get things wrong or don't generalize. None of that currently exists for MOTS-c. The 2019 BioEssays review on MOTS-c's role as a mitochondrial-encoded regulator of the nucleus ^[28] and the 2023 Diabetes & Metabolism Journal review connecting MOTS-c to diabetes and aging-related disease ^[29] both do a good job summarizing where the mechanistic science stands. Neither claims a human dosing trial has happened, because it hasn't been published if it has happened at all. Until that trial exists, treat "MOTS-c dosage calculator" as a research gap dressed up as a product feature. The honest answer to how much MOTS-c a person should take is: nobody outside a small number of unregistered protocols actually knows yet, and the people telling you otherwise are extrapolating from mice.

Frequently asked questions

Is there a scientifically validated MOTS-c dosage calculator?

No. No published human dose-response or pharmacokinetic trial for MOTS-c exists, so no calculator can be built from validated data. Every calculator online is extrapolating from animal studies, like the 2015 Cell Metabolism mouse work, or from community-reported practice, not from confirmed human dosing science.

What dose of MOTS-c was used in the original mouse studies?

The foundational 2015 Cell Metabolism study used mouse dosing protocols to demonstrate reduced obesity and improved insulin resistance in diet-induced obese mice; specific mg/kg figures are reported in that paper's methods, but mouse doses do not translate directly to human doses due to differences in metabolism and clearance rate.

Can MOTS-c really mimic the effects of exercise?

Some animal research, including a 2025 Scientific Reports study on diabetic liver fibrosis, found MOTS-c mimicked specific exercise-associated effects in that model. This supports a mitohormesis hypothesis discussed in a 2022 Diabetes & Metabolism Journal review, but it is not evidence that any dose replicates the full physiological benefit of actual exercise in humans.

Why don't dosage calculators account for body weight properly?

Most do use body weight as an input, applying an allometric scaling formula from animal mg/kg data. The problem isn't ignoring weight, it's that the underlying conversion factor from mouse to human has never been confirmed by an actual human pharmacokinetic study, so the output looks precise but rests on an unverified assumption.

Is MOTS-c FDA approved?

No. MOTS-c does not appear in the Drugs@FDA database of approved drug products. Its status under compounding law is unsettled; FDA maintains bulk drug substance lists under 21 CFR 216.23 (503A) and 21 CFR 216.24 (503B), and whether MOTS-c qualifies under either is a live regulatory question.

What health effects does MOTS-c actually have evidence for?

Evidence spans obesity and insulin resistance in mice, muscle atrophy and myostatin signaling, bone metabolism, lung injury models, and even ovarian cancer progression in cell and animal studies. Nearly all of it is preclinical (rodent or cell-based). Human clinical trial data on health outcomes is essentially absent from the published literature.

How is MOTS-c typically administered by people using it now?

Community and provider-guided use typically involves subcutaneous injection, though no standardized administration protocol has been validated in a published human trial. For details on timing, injection sites, and cycle length, see the dedicated dosing pages rather than relying on generic online calculators.

Does MOTS-c dosage differ for men versus women?

No published human data addresses sex-specific dosing for MOTS-c. Preclinical work, including a 2022 Pharmacological Research study on gestational diabetes, has examined female-specific physiological contexts, but that is disease-model research, not a dosing comparison between sexes.

What's the biggest risk of using an online MOTS-c dosage calculator?

The main risk is false confidence: a calculator that outputs a specific milligram figure implies a level of validated precision that doesn't exist for this peptide. Without provider oversight and baseline labs, you have no way to confirm the number is appropriate for your physiology or to catch an adverse response early.

How long do people typically stay on a MOTS-c protocol?

Reported cycle lengths vary widely across community use and are not derived from a validated clinical protocol. See our dedicated page on MOTS-c cycle length for how these timeframes are typically structured and what the reasoning behind them actually is.

Are there safety studies on MOTS-c in humans?

A 2026 Sports Medicine review on peptide therapies for musculoskeletal and athletic use catalogs safety and efficacy data across approved and unapproved peptides broadly, and MOTS-c falls among the compounds with limited human safety data published so far. Most safety signals to date come from animal and cell studies.

Should I get MOTS-c through a compounding pharmacy instead of using a calculator?

A provider-reviewed route, where a clinician or compounding pharmacy evaluates your labs and health history before recommending a dose, is safer than a self-service calculator with no medical oversight. It doesn't guarantee a validated dose, since that data doesn't exist yet, but it adds a layer of clinical judgment a website tool cannot.

Sources

1. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide for therapeutic exploitation, reflecting early-stage research status
2. PubMed, Cell Metabolism 2015 (PMID 25738459): MOTS-c administration promoted metabolic homeostasis and reduced obesity and insulin resistance in mouse studies
3. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppressed ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination
4. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus model
5. PubMed, Redox Biology 2025 (PMID 40403491): MOTS-c attenuated lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation and antioxidant gene activation
6. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress
7. PubMed, Metabolites 2023 (PMID 36677050): Review describing MOTS-c's functional role in preventing metabolic disorders
8. PubMed, Cardiovascular Drugs and Therapy 2025 (PMID 40172798): Review examining MOTS-c's potential role in diabetic cardiomyopathy
9. PubMed, iScience 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
10. PubMed, BioEssays 2019 (PMID 31378979): Review describing MOTS-c as a mitochondrial-encoded regulator of nuclear gene expression across contexts
11. PubMed, Sports Medicine 2026 (PMID 41966639): Review of safety and efficacy data for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance
12. PubMed, Peptides 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
13. PubMed, American Journal of Physiology-Endocrinology and Metabolism 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
14. PubMed, Frontiers in Physiology 2023 (PMID 37200834): Review of MOTS-c's role in regulating bone metabolism
15. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in osteoarthritis via an Nrf2-dependent mechanism
16. PubMed, Gut 2024 (PMID 37788894): MOTS-c has an antiviral role during hepatitis B infection via mitochondrial remodeling
17. PubMed, Theranostics 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation to the membrane
18. PubMed, European Journal of Pharmacology 2023 (PMID 37290680): MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion via PPARγ signaling
19. PubMed, Mitochondrion 2023 (PMID 37307934): MOTS-c is discussed as a potential anti-pulmonary fibrosis factor derived by mitochondria
20. PubMed, International Immunopharmacology 2025 (PMID 40472776): MOTS-c attenuates airway barrier dysfunction in allergic asthma by inhibiting epithelial apoptosis via the Nrf2 pathway
21. PubMed, Diabetes & Metabolism Journal 2023 (PMID 36824008): Review connecting MOTS-c to diabetes and aging-related diseases
22. PubMed, American Journal of Respiratory Cell and Molecular Biology 2025 (PMID 40035775): MOTS-c promotes glycolysis via the AMPK-HIF-1α-PFKFB3 pathway to ameliorate cardiopulmonary bypass-induced lung injury
23. PubMed, Experimental & Molecular Medicine 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes in studied models
24. PubMed, Autophagy 2026 (PMID 42153537): MOTS-c ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation
25. PubMed, American Journal of Physiology-Endocrinology and Metabolism 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling in studied models
26. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): Review of the relationship between mitochondrial-derived peptides and exercise
27. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): Review describing the mitohormesis hypothesis connecting exercise and MOTS-c
28. PubMed, Rejuvenation Research 2018 (PMID 30058454): Mitochondrial-derived peptides were found to exacerbate senescence in certain studied contexts
29. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimics exercise effects to combat diabetic liver fibrosis by targeting the Keap1-Nrf2-Smad2/3 pathway in an animal model
30. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the bulk drug substance list governing 503A pharmacy compounding
31. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the separate bulk drug substance list governing 503B outsourcing facility compounding
32. Cornell Law, 21 U.S.C. 353a: Establishes the statutory framework for pharmacy compounding under section 503A
33. FDA, bulk drug substances used in compounding under section 503A: Explains FDA's framework for evaluating and listing bulk drug substances for 503A compounding
34. FDA, bulk drug substances nominated for use in compounding (current list): FDA's current list of nominated bulk drug substances under review for 503A compounding use
35. Drugs@FDA database: MOTS-c does not appear as an FDA-approved drug product in this database